Abstract | BACKGROUND: METHODS: This meta-analysis was conducted based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses ( PRISMA) guideline. Eligible studies were pooled and the overall odds ratios ( ORs) and hazard ratios (HRs) with the corresponding 95% confidence intervals (95% CIs) were calculated in this analysis. RESULTS: Four studies involving a total of 527 patients with high-grade osteosarcoma receiving neoadjuvant chemotherapy were identified. We did not find that P16 expression was correlated with sex status, histologic subtype, and tumor site (P > .1). P16 expression was found to be significantly associated with a "good" response to neoadjuvant chemotherapy (OR = 4.69, P < .001). A significant relationship was observed between p16 expression and pathologic complete response after neoadjuvant chemotherapy using multivariate analysis (OR = 9.63, P = .001). The expression of the P16 was not associated with clinical outcomes in overall survival (OS) and disease-free survival (DFS) by multivariate analysis (OS: P = .448; DFS: P = .263). CONCLUSIONS: The use of P16 expression could become a promising predictive biomarker of the response to neoadjuvant chemotherapy in the white population with high-grade osteosarcoma. However, it was not correlated with the prognosis of patients in OS and DFS. More clinical researches are very essential in Asians in the future.
|
Authors | Yin Tang, Changchun Yang, Zonghui Guo, Youwei Fu, Xiao Yu, Binggen Liu, Haier Zhou, Junjie Wang, Weilong Li, Qingjiang Pang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 96
Issue 19
Pg. e6714
(May 2017)
ISSN: 1536-5964 [Electronic] United States |
PMID | 28489748
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Biomarkers, Tumor
- CDKN2A protein, human
- Cyclin-Dependent Kinase Inhibitor p16
|
Topics |
- Biomarkers, Tumor
(metabolism)
- Bone Neoplasms
(drug therapy, metabolism, pathology)
- Chemotherapy, Adjuvant
- Cyclin-Dependent Kinase Inhibitor p16
(metabolism)
- Humans
- Neoadjuvant Therapy
- Neoplasm Grading
- Osteosarcoma
(drug therapy, metabolism, pathology)
- Prognosis
|